Compare Stocks → Warning: this could blow your mind (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ASNBNASDAQ:NVIVOTCMKTS:RGINOTCMKTS:UAHC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNBEKIMAS$0.61$0.52$0.55▼$1.75$3.54M0.373,162 shsN/ANVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsRGINRegenicin$0.00$0.00▼$0.00$20KN/A2,463 shs1.80 million shsUAHCUnited American Healthcare$0.02-0.4%$0.03$0.01▼$0.05$2.69M-1.4223,907 shs9,349 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNBEKIMAS0.00%0.00%+24.49%-1.61%-12.86%NVIVInVivo Therapeutics0.00%0.00%0.00%-58.87%-65.14%RGINRegenicin0.00%0.00%0.00%0.00%-92.86%UAHCUnited American Healthcare-0.43%-22.82%-15.75%+8.49%-10.40%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNBEKIMASN/AN/AN/AN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/AN/AN/AN/AN/AUAHCUnited American HealthcareN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNBEKIMASN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/AUAHCUnited American HealthcareN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNBEKIMASN/AN/AN/AN/A$0.03 per shareN/ANVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ARGINRegenicinN/AN/AN/AN/A($0.04) per shareN/AUAHCUnited American HealthcareN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNBEKIMAS-$290KN/A0.00∞N/AN/A-7,902.31%-5,274.01%N/ANVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ARGINRegenicin-$640KN/A0.00N/AN/AN/AN/AN/AN/AUAHCUnited American HealthcareN/AN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNBEKIMASN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/AN/AUAHCUnited American HealthcareN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNBEKIMASN/A0.120.12NVIVInVivo TherapeuticsN/A14.3014.30RGINRegenicinN/AN/AN/AUAHCUnited American HealthcareN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNBEKIMASN/ANVIVInVivo Therapeutics13.78%RGINRegenicin0.01%UAHCUnited American HealthcareN/AInsider OwnershipCompanyInsider OwnershipASNBEKIMAS7.80%NVIVInVivo Therapeutics2.45%RGINRegenicinN/AUAHCUnited American Healthcare14.31%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASNBEKIMAS115.80 million5.35 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableRGINRegenicin3165.77 millionN/ANot OptionableUAHCUnited American Healthcare33117.06 million100.31 millionNot OptionableNVIV, UAHC, RGIN, and ASNB HeadlinesSourceHeadlineSteward Health Care selling major part of operations to Optum Caremsn.com - March 28 at 7:14 AMUnitedHealth Group Pays $3 billion To Providers After Cyberattacktechbullion.com - March 28 at 7:14 AMMass. Sens. Warren, Markey push back against Steward, United proposalmsn.com - March 27 at 9:12 PMTake Advantage Of Medicare Benefits With UnitedHealthcare Medicare & Retirement Of Texasyahoo.com - March 27 at 4:11 PMAHA Letter to UnitedHealthcare RE: Molecular Pathology Reimbursement Policyaha.org - March 27 at 5:46 AMChange Healthcare Cyberattack: What Consumers Should Knowwebmd.com - March 25 at 5:33 PMUnitedHealth Announces Relief for Healthcare Workers After Cyberattack; Here's What They'll Getmsn.com - March 25 at 2:30 AMMassive cyberattack crippled a healthcare payment system a month ago. It’s not fixed yet.nj.com - March 20 at 7:32 PMMount Sinai and UnitedHealthcare reach dealnewsday.com - March 19 at 11:09 PMUnitedHealth Group recovering from significant cyberattack: CEOmsn.com - March 19 at 11:09 PMUnitedHealth Group Dispenses Over $2 Billion to Providers Post-Cyberattackmsn.com - March 19 at 12:50 PMUnitedHealth says it’s doled out $2 billion to health care providers after cyberattackspokesman.com - March 18 at 4:48 PMHealth Care Hack Exposes Deadly Flaws and Danger of Apathybloomberg.com - March 18 at 11:47 AMWill The Change Healthcare Incident Change Health Care?healthaffairs.org - March 15 at 9:29 AMThe best dataset on American health care will be harder to accesseconomist.com - March 14 at 1:23 PMAHA Urges More Congressional Action to Help Providers Affected By Change Healthcare Cyberattackaha.org - March 13 at 8:38 PMHealth care giant raises alarms about Corvallis Clinic, urges quick approval of acquisitionbizjournals.com - March 13 at 8:38 PMHealth care providers may be losing up to $100 million a day from cyberattack. A doctor shares the latestmsn.com - March 13 at 10:37 AMU.S. healthcare providers reeling from cyberattackupi.com - March 13 at 10:37 AMCyberattack leaves health care worker pay in limbocrainsdetroit.com - March 12 at 6:27 PMHawaii health plans impacted by the recent Change Healthcare cyberattackbizjournals.com - March 12 at 2:09 AMWhite House and lawmakers increase pressure on UnitedHealth to ease providers' painmsn.com - March 11 at 8:11 PMFeds extend support, press insurers on Change Healthcare outagemodernhealthcare.com - March 11 at 3:10 PMFebruary Hack on UnitedHealthcare: The worst of its kind, recovery time uncertainmsn.com - March 11 at 3:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines4 Stocks to Buy Before the Fed Cuts Interest RatesMarch 19, 2024 7:49 AMView 4 Stocks to Buy Before the Fed Cuts Interest RatesIs it Time to Buy These 5 Oversold Stocks?March 15, 2024 7:12 AMView Is it Time to Buy These 5 Oversold Stocks?Active Rebound: 2 Discrete Semiconductor Stocks Making MovesMarch 12, 2024 8:00 AMView Active Rebound: 2 Discrete Semiconductor Stocks Making MovesPalantir Stock Spikes 6% on U.S. Army TITAN ContractMarch 6, 2024 12:33 PMView Palantir Stock Spikes 6% on U.S. Army TITAN ContractOracle's AI Cloud Demand Fuels Profitability SurgeMarch 14, 2024 1:17 PMView Oracle's AI Cloud Demand Fuels Profitability SurgeAll Headlines Company DescriptionsEKIMASOTCMKTS:ASNBEKIMAS Corp. engages in the development of polymer materials, which provide characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. The firm's products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Las Vegas, NV.InVivo TherapeuticsNASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.RegenicinOTCMKTS:RGINRegenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.United American HealthcareOTCMKTS:UAHCUnited American Healthcare Corporation, through its subsidiaries, provides contract manufacturing services to the medical device industry. It also focuses on the production of natural rubber. The company was incorporated in 1983 and is based in Chicago, Illinois. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.